The rising prevalence of chronic diseases, such as cancer, cardiovascular diseases, and autoimmune disorders, acts as a significant driver in the U.S., Europe, and Japan blocking buffers market by increasing the demand for advanced diagnostic and research tools. Blocking buffers, which are critical in reducing background noise in assays, play a vital role in enhancing the accuracy and sensitivity of diagnostic tests like ELISA and Western blotting. With the growing incidence of chronic diseases, there is a heightened focus on research and development efforts to identify biomarkers, develop new therapeutic strategies, and improve disease detection methods. This surge in demand for precise diagnostic tools and personalized treatments has fueled the adoption of blocking buffers in both clinical and research settings, driving market growth across these regions. Also, the increasing investment in biotechnology and pharmaceutical sectors, aimed at addressing the rising burden of chronic illnesses, further amplifies the need for high-quality reagents like blocking buffers to support innovative diagnostic and therapeutic solutions.
Access Full Report @ https://www.databridgemarketresearch.com/pt/reports/us-blocking-buffers-market
Data Bridge Market Research analyzes that the U.S. Blocking Buffers Market is expected to reach USD 909.07 million by 2031 from USD 476.07 million in 2023 growing with a CAGR of 8.6% in the forecast period of 2024 to 2031.
Data Bridge Market Research analyzes that the Europe Blocking Buffers Market is expected to reach USD 587.07 million by 2031 from USD 285.67 million in 2023 growing with a CAGR of 9.6% in the forecast period of 2024 to 2031.
Data Bridge Market Research analyzes that the Japan Blocking Buffers Market is expected to reach USD 42.07 million by 2031 from USD 25.57 million in 2023 growing with a CAGR of 6.6% in the forecast period of 2024 to 2031.
Key Findings of the Study
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable 2016 - 2021)
|
|
Quantitative Units
|
Revenue in USD Million
|
|
Segments Covered
|
Type (BSA (Bovine Serum Albumin), Casein, Gelatin, Skimmed Milk, and Others), Composition (Salt Solution, Blocking Agents, Detergent, and Others), Form (Powder and Liquid), Product Type (Research Use and Commercial Use), Application (Western Blot, ELISA, Nucleic Acid Detection, Immunohistochemistry (IHC), and Others), End User (Research and Chemical Laboratories, Contract Research Organization, Pharmaceutical and Biotechnology Companies, Hospitals, Clinical Laboratories, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others)
|
|
Countries Covered
|
U.S., Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan,
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Merck KGAA (Germany), Bio-Rad Laboratories Inc. (U.S.), Takara Bio Inc. (Japan), Abcam Limited (U.K.), Associates of Cape Cod Inc. (U.S.), ANTIBODIES INCORPORATED (U.S.), Azure Biosystems Inc. (U.S.), Arlington Scientific, Inc (U.S.), , Advansta Inc. (U.S.), Boston Bioproducts (U.S.), Calbiotech (U.S.), Candor Bioscience GMBH (Germany), Eastcoast Bio (U.S.), Elabscience Bionovation Inc. (U.S.), Grace Bio-Labs (U.S.), Geno Technology Inc. USA (U.S.), Himedia Laboratories (India), Kementec (Denmark), Lifespan Biosciences, Inc (U.S.), Li-Cor Biotech, LLC (U.S.), Meridian Life Science (U.S.), Proteintech Group, Inc. (U.S.), Rockland Immunochemicals, Inc (U.S.), Scantibodies laboratory, Inc. (U.S.), Surmodics, Inc (U.S.), Sino Biological, Inc. (China), Thistle Scientific Ltd (U.K.) among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, patient epidemiology, pipeline analysis, and regulatory framework.
|
Segment Analysis
The U.S., Europe, and Japan blocking buffers market is segmented into seven notable segments based on type, form, composition, product type, application, end user, and distribution channel.
- ON the basis of type, the market is segmented into BSA (Bovine Serum Albumin), casein, gelatin, skimmed milk, and others
In 2024, the BSA (Bovine Serum Albumin) segment is expected to dominate the U.S., Europe, and Japan blocking buffers market
In 2024, BSA (Bovine Serum Albumin) segment in U.S. is expected to dominate the market with 36.02% market share
In 2024, BSA (Bovine Serum Albumin) segment in Europe is expected to dominate the market with 37.49% market share
In 2024, BSA (Bovine Serum Albumin) segment in Japan is expected to dominate the market with 41.77% market share
- On the basis of composition, the market is segmented into salt solution, blocking agents, detergent and others
In 2024, the salt solution segment is expected to dominate the U.S., Europe, and Japan blocking buffers market
In 2024, salt solution segment in U.S. is expected to dominate the market with 37.36% market share
In 2024, salt solution segment in Europe is expected to dominate the market with 38.80% market share
In 2024, salt solution segment in Japan is expected to dominate the market with 42.99% market share
- On the basis of form, the market is segmented into powder and liquid. In 2024, powder segment in U.S. is expected to dominate the market with 56.72% market share. In 2024, powder segment in Europe is expected to dominate the market with 57.71% market share. In 2024, powder segment in Japan is expected to dominate the market with 60.61% market share
- On the basis of product type, market is segmented into research use and commercial use. In 2024, research use segment in U.S. is expected to dominate the market with 62.45% market share. In 2024, research use segment in Europe is expected to dominate the market with 63.31% market share. In 2024, research use segment in Japan is expected to dominate the market with 65.82% market share
- On the basis of application, the market is segmented into Western Blot, ELISA, Nucleic Acid Detection, Immunohistochemistry (IHC) and others. In 2024, western blot segment in U.S. is expected to dominate the market with 34.57% market share. In 2024, western blot segment in Europe is expected to dominate the market with 36.07% market share. In 2024, western blot segment in Japan is expected to dominate the market with 40.44% market share
- On the basis of end user, the market is segmented into research and chemical laboratories, contract research organization, pharmaceutical and biotechnology companies, hospitals, clinical laboratories and others. In 2024, research and chemical laboratories segment in U.S, is expected to dominate the market with 28.76% market share. In 2024, research and chemical laboratories segment in Europe is expected to dominate the market with 30.39% market share. In 2024, research and chemical laboratories segment in Japan is expected to dominate the market with 35.16% market share
- On the basis of distribution channel, the market is segmented into direct tender, retail sales and others. In 2024, direct tender segment in U.S. is expected to dominate the market with 60.30% market share. In 2024, direct tender segment in Europe is expected to dominate the market with 61.21% market share. In 2024, direct tender segment in Japan is expected to dominate the market with 63.87% market share
Major Players
Data Bridge Market Research analyzes F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Merck KGAA (Germany), Bio-Rad Laboratories Inc. (U.S.), Takara Bio Inc. (Japan) as major market players in this market.
Market Developments
- In May 2023, Teva and Alvotech announced SIMLANDI (adalimumab-ryvk) Injection now available in the U.S. announced the availability of SIMLANDI (adalimumab-ryvk) injection in the U.S., as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa, including aplastic anemia, and adult uveitis
- In December 2022, Shield Therapeutics and Viatris sign Collaborative Sales Agreement for Accrufer in the United States. Accrufer is the only FDA approved oral iron to treat iron deficiency, with or without anemia. This new collaboration expands the commercial footprint and resources for Accrufer, as the brand aspires to be the oral iron of choice in the US market. The collaboration will result in a 100 person sales team who will promote Accrufer to over 12,000 Health Care Professionals who write the majority of oral iron prescriptions
Country Analysis
Geographically, the countries covered this market are U.S., Japan, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, and rest of Europe.
As per Data Bridge Market Research analysis:
Germany is expected to dominate and fastest growing country in the U.S., Europe, and Japan blocking buffers market because increased adoption of western blot and ELISA techniques.
For more detailed information about the U.S., Europe, and Japan blocking buffers market report, click here – https://www.databridgemarketresearch.com/pt/reports/us-blocking-buffers-market
